© Reuters. FILE PHOTO: A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble
(Reuters) – AstraZeneca (NASDAQ:) said on Friday it had appointed Alexion (NASDAQ:)’s Aradhana Sarin as its new chief financial officer as it shifts existing CFO Marc Dunoyer to a new role leading the U.S.-based drugmaker after the pair’s merger.
AstraZeneca agreed to buy Alexion in December in its largest ever deal, a bet on rare-disease immunology which also includes a fast-growing cancer medicines unit and a major COVID-19 vaccine.
London-listed AstraZeneca said Sarin’s appointment was conditional upon the completion of its $39 billion buyout of Alexion.
Dunoyer will become the U.S. drugmaker’s chief executive officer while also being appointed chief strategy officer at AstraZeneca. He will leave the Anglo-Swedish company’s board but continue to report to CEO Pascal Soriot.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Be the first to comment